Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies.
Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT).
This process of inducing tolerance to the allergen requires 3-5 years – time that could be saved with Anergis’ products.
Following the completion of phase II trials, Anergis is advancing it leading programme, AllerT for birch allergies. A phase IIb trial is in the making, that will access efficacy and tolerability of two dosing regimens of AllerT In Adults with Birch Pollen AllergicRhinitis/ Rhinoconjunctivitis (ATIBAR).
ATIBAR is expected to start in the Fall of 2016, with a total of 450 patients. Results are expected in the third quarter of 2017.
This trial is designed meet both European and US FDA efficacy criteria for allergy immunotherapy products. After this, one more confirmatory efficacy phase III trial will be required before registration,